May 14, 2018 by Brian Orelli, PhDCelgene Starts the Year With a BangA solid first quarter and some acquisitions to boot.
May 11, 2018 by Brian Orelli, PhDIDEXX Laboratories Barks Out Another Successful QuarterThe animal-diagnostics company posts another quarter of double-digit growth.
May 11, 2018 by Brian Orelli, PhDWhy Akcea Therapeutics Rocketed Higher TodayAn FDA advisory committee endorsed the biotech's lead drug, but an approval is far from a slam dunk.
May 10, 2018 by Brian Orelli, PhDWhy Exelixis Dropped TodayThe company announced a disappointing clinical trial failure, which fortunately wasn't for its top-selling drug.
May 10, 2018 by Brian Orelli, PhDWhy Diplomat Pharmacy Stock Jumped TodayInvestors are excited about the company's new leadership.
May 9, 2018 by Brian Orelli, PhDbluebird bio Looks for Data AheadAn uneventful first quarter, but the biotech has data coming later in the year.
May 9, 2018 by Brian Orelli, PhDIonis Pharmaceuticals Prepares for LaunchThe biotech has the potential for two FDA approvals this year.
May 8, 2018 by Brian Orelli, PhDImmunoGen Presses ForwardThe biotech waits for clinical trial results for its lead drug, mirvetuximab.
May 8, 2018 by Brian Orelli, PhDEmergent BioSolutions Moves Things AroundDelayed shipments don't affect the bioterrorism company's 2018 forecast.
May 8, 2018 by Brian Orelli, PhDWhy Sangamo Therapeutics Stock Dropped TodayValuing early-stage biotechs is hard.
May 8, 2018 by Brian Orelli, PhDAlnylam Looks ForwardAn uneventful earnings release as the company anticipates an approval of its hereditary TTR amyloidosis drug, patisiran.
May 7, 2018 by Brian Orelli, PhDBecton, Dickinson Starts the Bard Integration Off on a Solid NoteThe medical supply company looks for margin expansion in the coming quarters.
May 7, 2018 by Brian Orelli, PhDQiagen Starts Slowly but Is On TrackThe launch of QIAstat-Dx should help accelerate growth in the second half of the year.
May 7, 2018 by Brian Orelli, PhDNovo Nordisk Fights Payer Pressure With New MedsSales of older medications are on the decline, but newer medications helped the revenue line grow at constant exchange rates.
May 4, 2018 by Brian Orelli, PhDWhy Acadia Pharmaceuticals Jumped 11% Higher TodayFirst-quarter revenue growth has investors excited.
May 4, 2018 by Brian Orelli, PhDExelixis Reaccelerates GrowthAn expanded approval has the biotech's cancer drug Cabometyx headed in the right direction.
May 4, 2018 by Brian Orelli, PhDGenomic Health Starts the Year off RightA solid start for the cancer-test specialist.
May 2, 2018 by Brian Orelli, PhDWhy Tenet Healthcare Is on a 29% Two-Day Run HigherThe hospital operator is off to a good start in 2018, but can it last?
May 2, 2018 by Brian Orelli, PhDSeattle Genetics Accelerates Revenue Growth, Earnings Not So MuchAn expanded approval has doctors prescribing the biotech's blood cancer drug, Adcertis, to more patients.
May 1, 2018 by Brian Orelli, PhDWhy Marijuana Stock Cronos Dropped 10% TodayIt's hard to value markets in a high-growth industry.
